The company said it has made significant recent progress with its four clinical assets and proprietary Guardian Angel algorithm.
LAM-002 is a first-in-class, PIKfyve kinase inhibitor that activates transcription factor EB, the master regulator of lysosomal biogenesis.1 TFEB activation clears toxic aggregates that drive neurodegenerative disorders.
Through its action on the lysosome, LAM-002 also selectively kills tumor cells.
AI Therapeutics has recently completed enrollment in a clinical trial with patients previously treated for follicular lymphoma.
Efficacy has been observed with LAM-002 as a single agent and when combined with rituximab or atezolizumab.
LAM-002 appears to be well-tolerated with patients on continuous treatment for well over a year.
AI Therapeutics said it had a Type C meeting with the US Food and Drug Administration to discuss the registrational programme for LAM-002 in patients with previously treated follicular lymphoma.
At this meeting, AI Therapeutics reached concurrence on the design of a pivotal trial that could support accelerated approval.
The clinical data to support full approval in patients with previously treated follicular lymphoma was also discussed and a path forward was detailed.
LAM-002 has received Fast Track status and Orphan Drug Designation from the FDA for the therapy of follicular lymphoma. The safety and clinical data for LAM-002 are expected to be presented at the American Society of Clinical Oncology conference in 2020.
AI Therapeutics has built a deep learning platform, Guardian Angel, that synthesises public and proprietary data on drugs and diseases and finds new indications for our library of new chemical entities.
Aided by Guardian Angel the company now has four drugs in the clinic, including drugs that shrink cancers, the most promising candidate to treat ALS (Lou Gehrig's disease), and drugs with applications for longevity.
AI Therapeutics is a 4Catalyzer company, and benefits from the advantages of being part of an incubator with >300 scientists and engineers, and offices in Connecticut, New York, Silicon Valley, and Taiwan.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial